Cencora Inc. (COR)vsNovo Nordisk A/S (NVO)
COR
Cencora Inc.
$261.08
+2.12%
HEALTHCARE · Cap: $49.74B
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 0% more annual revenue ($328.68B vs $327.80B). NVO leads profitability with a 37.2% profit margin vs 0.8%. COR appears more attractively valued with a PEG of 0.73. NVO earns a higher WallStSmart Score of 74/100 (B).
COR
Buy64
out of 100
Grade: C+
NVO
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.1%
Fair Value
$1266.50
Current Price
$261.08
$1005.42 discount
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 107 in profit
Earnings expanding 128.3% YoY
Growing faster than its price suggests
Generating 1.2B in free cash flow
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Areas to Watch
3.8% revenue growth
0.8% margin — thin
Operating margin of 1.7%
Trading at 26.6x book value
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, EPS Growth, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : COR
The primary concerns for COR are Revenue Growth, Profit Margin, Operating Margin. Thin 0.8% margins leave little buffer for downturns.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
COR profiles as a value stock while NVO is a growth play — different risk/reward profiles.
COR carries more volatility with a beta of 0.65 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 64/100), backed by strong 37.2% margins and 24.0% revenue growth. COR offers better value entry with a 71.1% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?